Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282023 | 0.88 | POLB (0.53) | ADORA3ADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL3071322 | 0.87 | ADORA3 (0.62) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL6286094 | 0.85 | ALDH1A1 (0.73) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL27736015 | 0.83 | ADORA3 (0.58) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL6283239 | 0.81 | ADORA3 (0.69) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL10206293 | 0.81 | ABL1 (0.58) | ABL1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4110096 | 0.78 | ALDH1A1 (0.82) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL6545438 | 0.78 | ADORA3 (0.63) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL6546546 | 0.77 | MAPT (0.88) | ADORA3ADORA2BALDH1A1MAPTMEN1 | |
| SCHEMBL6278341 | 0.76 | ALDH1A1 (0.62) | ADORA3ADORA2BALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | ADORA3 1613/4885ADORA2B 1833/4885ABL1 1078/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | ADORA3 2584/4885ADORA2B 1923/4885ABL1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.